Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEARLS / KEYNOTE-091 adjuvant pembrolizumab versus placebo in resected early-stage NSCLC
2023-509137-39-00Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 27
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Pembrolizumab with Placebo (2 arms). Primary endpoints: Disease-free survival in the PD-L1 strong positive subgroup and Disease-free survival in the overall population. Started Jul 2024; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-509137-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509137-39-00.